March 2013 Distributions for Market Vectors Bank and Brokerage ETF and Market Vectors Pharmaceutical
March 2013 Distributions for Market Vectors Bank and Brokerage ETF and Market Vectors Pharmaceutical ETF
NEW YORK--(BUSINESS WIRE)-- The Market Vectors ETF Trust announced today the March 2013 distributions per share for the Market Vectors Bank and Brokerage ETF and Market Vectors Pharmaceutical ETF.
The following dates apply to today's distribution declarations:
|April 1, 2013||April 3, 2013||April 5, 2013|
|Market Vectors Bank and Brokerage ETF||Quarterly||$0.3700|
|Market Vectors Pharmaceutical ETF||Quarterly||$0.3890|
The majority, and possibly all, of these distributions will be paid out of net investment income earned by the Funds. A portion of this distribution may come from net short-term realized capital gains or return of capital.
The amount of dividends paid by each fund may vary from time to time. Past amounts of dividends are no guarantee of future dividend payment amounts.
Market Vectors does not provide legal, tax or accounting advice. Any statement contained in this communication concerning U.S. tax matters is not intended or written to be used, and cannot be used, for the purpose of avoiding penalties imposed on the relevant taxpayer. Shareholders or potential shareholders of the Market Vectors ETFs should obtain their own independent tax advice based on their particular circumstances.
About Market Vectors ETFs
Market Vectors exchange-traded products have been offered since 2006 and span many asset classes, including equities, fixed income (municipal and international bonds) and currency markets. The Market Vectors family currently totals $26.4 billion in assets under management, making it the fifth largest ETP family in the U.S. and eighth largest worldwide as of December 31, 2012.
Market Vectors ETFs are sponsored by Van Eck Global. Founded in 1955, Van Eck Global was among the first U.S. money managers helping investors achieve greater diversification through global investing. Today, the firm continues this tradition by offering innovative, actively managed investment choices in hard assets, emerging markets, precious metals including gold, and other alternative asset classes. Van Eck Global has offices around the world and manages approximately $36.6 billion in investor assets as of December 31, 2012.
Please call 888.MKT.VCTR or visit our website for the most recent month-end performance of Market Vectors ETFs. This information will be available no later than seven business days after the most recent month end.
Principal Fund Risk Factors: Investors should be willing to accept substantial risk, a high degree of volatility and the potential of significant loss. The principal risks of investing in Market Vectors ETFs include sector, market, economic, political, foreign currency, world event, index tracking and non-diversification risks, as well as fluctuations in net asset value and the risks associated with investing in less developed capital markets. The Funds may loan their securities, which may subject them to additional credit and counterparty risk.
Market Vectors Bank and Brokerage ETF Risk: Investments concentrated in the bank and brokerage sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, changes in interest rates, market cycles and economic conditions, significant competition and extensive state and federal regulation. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies.
Market Vectors Pharmaceutical ETF Risk: Investments concentrated in the pharmaceutical sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, costs associated with research and development, intellectual property rights and regulatory approval by the U.S. Food and Drug Administration. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies.
Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market.
Investors may call 888.MKT.VCTR or visitmarketvectorsetfs.comfor a freeprospectusandsummary prospectus.Investing involves risk, including possible loss of principal. An investor should consider the investment objective, risks, and charges and expenses of Market Vectors ETFs carefully before investing. The prospectus and summary prospectus contains this and other information. Please read the prospectus and summary prospectus carefully before investing.
Van Eck Securities Corporation, Distributor, 335 Madison Avenue, New York, NY 10017
Mike MacMillan/Chris Sullivan
KEYWORDS: United States North America New York
The article March 2013 Distributions for Market Vectors Bank and Brokerage ETF and Market Vectors Pharmaceutical ETF originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.